211 related articles for article (PubMed ID: 32516365)
1. Screening novel drug candidates for Alzheimer's disease by an integrated network and transcriptome analysis.
Peng Y; Yuan M; Xin J; Liu X; Wang J
Bioinformatics; 2020 Nov; 36(17):4626-4632. PubMed ID: 32516365
[TBL] [Abstract][Full Text] [Related]
2. Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer's disease patients.
Bayraktar A; Li X; Kim W; Zhang C; Turkez H; Shoaie S; Mardinoglu A
J Transl Med; 2023 May; 21(1):332. PubMed ID: 37210557
[TBL] [Abstract][Full Text] [Related]
3. AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer's drug discovery.
Zhou Y; Fang J; Bekris LM; Kim YH; Pieper AA; Leverenz JB; Cummings J; Cheng F
Alzheimers Res Ther; 2021 Jan; 13(1):24. PubMed ID: 33441136
[TBL] [Abstract][Full Text] [Related]
4. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
Shoaib M; Kamal MA; Rizvi SMD
Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human Interactome.
Chatterjee P; Roy D; Rathi N
J Alzheimers Dis; 2018; 61(1):53-65. PubMed ID: 29199645
[TBL] [Abstract][Full Text] [Related]
6. PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures.
Emon MA; Domingo-Fernández D; Hoyt CT; Hofmann-Apitius M
BMC Bioinformatics; 2020 Jun; 21(1):231. PubMed ID: 32503412
[TBL] [Abstract][Full Text] [Related]
7. deepDR: a network-based deep learning approach to in silico drug repositioning.
Zeng X; Zhu S; Liu X; Zhou Y; Nussinov R; Cheng F
Bioinformatics; 2019 Dec; 35(24):5191-5198. PubMed ID: 31116390
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's disease master regulators analysis: search for potential molecular targets and drug repositioning candidates.
Vargas DM; De Bastiani MA; Zimmer ER; Klamt F
Alzheimers Res Ther; 2018 Jun; 10(1):59. PubMed ID: 29935546
[TBL] [Abstract][Full Text] [Related]
9. A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer's Disease.
Lee SY; Song MY; Kim D; Park C; Park DK; Kim DG; Yoo JS; Kim YH
Front Pharmacol; 2019; 10():1653. PubMed ID: 32063857
[TBL] [Abstract][Full Text] [Related]
10. Analyzing the genes related to Alzheimer's disease via a network and pathway-based approach.
Hu YS; Xin J; Hu Y; Zhang L; Wang J
Alzheimers Res Ther; 2017 Apr; 9(1):29. PubMed ID: 28446202
[TBL] [Abstract][Full Text] [Related]
11. Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease.
Kim TW
Neurotherapeutics; 2015 Jan; 12(1):132-42. PubMed ID: 25549849
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers of Alzheimer's Disease Associated with Programmed Cell Death Reveal Four Repurposed Drugs.
Kubat Oktem E
J Mol Neurosci; 2024 May; 74(2):51. PubMed ID: 38700745
[TBL] [Abstract][Full Text] [Related]
13. A novel computational approach for drug repurposing using systems biology.
Peyvandipour A; Saberian N; Shafi A; Donato M; Draghici S
Bioinformatics; 2018 Aug; 34(16):2817-2825. PubMed ID: 29534151
[TBL] [Abstract][Full Text] [Related]
14. Cogena, a novel tool for co-expressed gene-set enrichment analysis, applied to drug repositioning and drug mode of action discovery.
Jia Z; Liu Y; Guan N; Bo X; Luo Z; Barnes MR
BMC Genomics; 2016 May; 17():414. PubMed ID: 27234029
[TBL] [Abstract][Full Text] [Related]
15. Drug Repurposing for Alzheimer's Disease Based on Protein-Protein Interaction Network.
Soleimani Zakeri NS; Pashazadeh S; MotieGhader H
Biomed Res Int; 2021; 2021():1280237. PubMed ID: 34692825
[TBL] [Abstract][Full Text] [Related]
16. Identification of molecular signatures and pathways to identify novel therapeutic targets in Alzheimer's disease: Insights from a systems biomedicine perspective.
Rahman MR; Islam T; Zaman T; Shahjaman M; Karim MR; Huq F; Quinn JMW; Holsinger RMD; Gov E; Moni MA
Genomics; 2020 Mar; 112(2):1290-1299. PubMed ID: 31377428
[TBL] [Abstract][Full Text] [Related]
17. Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in Alzheimer's disease.
Chrétien B; Jourdan JP; Davis A; Fedrizzi S; Bureau R; Sassier M; Rochais C; Alexandre J; Lelong-Boulouard V; Dolladille C; Dallemagne P
Br J Clin Pharmacol; 2021 Jul; 87(7):2830-2837. PubMed ID: 33274491
[TBL] [Abstract][Full Text] [Related]
18. Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining.
Zhang M; Schmitt-Ulms G; Sato C; Xi Z; Zhang Y; Zhou Y; St George-Hyslop P; Rogaeva E
PLoS One; 2016; 11(12):e0168812. PubMed ID: 28005991
[TBL] [Abstract][Full Text] [Related]
19. Old Drugs with New Tricks: Paradigm in Drug Development Pipeline for Alzheimer's Disease.
Dalvi T; Dewangan B; Das R; Rani J; Shinde SD; Vhora N; Jain A; Sahu B
Cent Nerv Syst Agents Med Chem; 2020; 20(3):157-176. PubMed ID: 33087034
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel immune-relevant drug target genes for Alzheimer's Disease by combining ontology inference with network analysis.
Han ZJ; Xue WW; Tao L; Zhu F
CNS Neurosci Ther; 2018 Dec; 24(12):1253-1263. PubMed ID: 30106219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
